ArticleOncogene2005
Molecular signature of retinoic acid treatment in acute promyelocytic leukemia.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 54 citations in OpenAlex.
- USP22 regulates APL differentiation via PML-RARα stabilization and IFN repression.Cell death discovery · 2024Article
- Repurposing Drugs in Small Animal Oncology.Animals : an open access journal from MDPI · 2022Review
- Review
- Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia.Blood advances · 2018Article
- Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.Cancer discovery · 2017Article
- Opposite Effects of SET7/9 on Apoptosis of Human Acute Myeloid Leukemia Cells and Lung Cancer Cells.Journal of Cancer · 2017Article
- PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.Oncotarget · 2016Article
- HIF factors cooperate with PML-RARα to promote acute promyelocytic leukemia progression and relapse.EMBO molecular medicine · 2014Article
- Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia.Oncotarget · 2014Article
- Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.Nature medicine · 2014Article
- Notch signaling in acute promyelocytic leukemia.Leukemia · 2013Article
- PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice.Haematologica · 2013Article
- PKCδ Regulates Translation Initiation through PKR and eIF2α in Response to Retinoic Acid in Acute Myeloid Leukemia Cells.Leukemia research and treatment · 2012Article
- Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation.Leukemia · 2010Article
- AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.PLoS genetics · 2008Article
- MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks.Molecular and cellular biology · 2008Article
- Article
- MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.Oncogene · 2007Article
- Molecular concepts analysis links tumors, pathways, mechanisms, and drugs.Neoplasia (New York, N.Y.) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a block of differentiation at the promyelocytic stage. APL patients respond to pharmacological concentrations of all-trans retinoic acid (RA) and disease remission correlates with terminal differentiation of leukemic blasts. The PML/RAR oncogenic transcription factor is responsible for both the pathogenesis of APL and for its sensitivity to RA. In order to identify physiological targets of RA therapy, we analysed gene expression profiles of RA-treated APL blasts and found 1056 common target genes. Comparing these results to those obtained in RA-treated U937 cell lines revealed that transcriptional response to RA is largely dependent on the expression of PML/RAR. Several genes involved in the control of differentiation and stem cell renewal are early targets of RA regulation, and may be important effectors of RA response. Modulation of chromatin modifying genes was also observed, suggesting that specific structural changes in local chromatin domains may be required to promote RA-mediated differentiation. Computational analysis of upstream genomic regions in RA target genes revealed nonrandom distribution of transcription factor binding sites, indicating that specific transcriptional regulatory complexes may be involved in determining RA response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.